Biblio

Samson M, Devilliers H, Ly KHeang, Maurier F, Bienvenu B, Terrier B, Charles P, Guillevin L, Besancenot J-F, Liozon E et al..  2018.  Tocilizumab as an add-on therapy to glucocorticoids during the first 3 months of treatment of Giant cell arteritis: A prospective study. EUROPEAN JOURNAL OF INTERNAL MEDICINE. 57:96-104.

Samson M, Devilliers H, Ly KHeang, Maurier F, Bienvenu B, Terrier B, Charles P, Besancenot J-F, Fauchais A-L, Binquet C et al..  2016.  Tocilizumab As an Add-on Therapy to Glucocorticoids during the First 3 Months of Treatment of Giant Cell Arteritis: Results of a French Multicenter Prospective Open-Label Study. ARTHRITIS & RHEUMATOLOGY. 68

Toussirot E, Govindaraju S, Mekinian A.  2020.  Tocilizumab failure in malignancy -related polymyalgia rheumatica. JOINT BONE SPINE. 87:366-368.

Bielefeld P, Baudin F, Blanc J, Bron A, Mouries-Martin S, Bouvet R, Devilliers H.  2019.  TOCILIZUMAB FOR REFRACTORY DYSTHYROID MYOPATHY (RDM) : A MONOCENTER OBSERVATIONAL STUDY OF 8 PATIENTS. ANNALS OF THE RHEUMATIC DISEASES. 78:2005.

Maldiney T, Deschasse C, Bielefeld P.  2020.  Tocilizumab for the Management of Corticosteroid-Resistant Mild to Severe Graves' Ophthalmopathy, a Report of Three Cases. OCULAR IMMUNOLOGY AND INFLAMMATION. 28:281-284.

Regent A, Redeker S, Deroux A, Kieffer P, Ly KHeang, Dougados M, Larroche C, Guillevin L, Bouillet L, Espitia O et al..  2015.  Tocilizumab in Giant Cell Arteritis: A Multicentre Open-Label Study in France. ARTHRITIS & RHEUMATOLOGY. 67

Regent A., Redeker S., Deroux A., Kieffer P., Ly K., Dougados M., Eric L., Larroche C., Guillevin L., Bouillet L. et al..  2016.  TOCILIZUMAB IN GIANT CELL ARTERITIS: A MULTICENTRE OPEN-LABEL STUDY OF34 PATIENTS. ANNALS OF THE RHEUMATIC DISEASES. 75:794.

Regent A., Redeker S., Deroux A., Kieffer P., Ly K., Dougados M., Liozon E., Larroche C., Guillevin L., Bouillet L. et al..  2016.  Tocilizumab in giant cell arteritis: a multicentre open-label study of 34 patients. FUNDAMENTAL & CLINICAL PHARMACOLOGY. 30:7.

Regent A, Redeker S, Deroux A, Kieffer P, Ly KHeang, Dougados M, Larroche C, Guillevin L, Bouillet L, Espitia O et al..  2015.  Tocilizumab in Giant Cell Arteritis: A Multicentre Open-Label Study in France. ARTHRITIS & RHEUMATOLOGY. 67

Papo M., Bielefeld P., Vallet H., Seve P., Wechsler B., Cacoub P., Le Hoang P., Papo T., Bodaghi B., Saadoun D..  2014.  Tocilizumab in severe and refractory non-infectious uveitis. CLINICAL AND EXPERIMENTAL RHEUMATOLOGY. 32:S75-S79.

Fortunet C, Pers Y-M, Lambert J, Godfrin-Valnet M, Constant E, Devilliers H, Gaudin P, Jorgensen C, Prades BPallot, Wendling D et al..  2015.  Tocilizumab induces corticosteroid sparing in rheumatoid arthritis patients in clinical practice. RHEUMATOLOGY. 54:672-677.

Sjostrand J, Vogel M.  2021.  Toeplitz band matrices with small random perturbations. INDAGATIONES MATHEMATICAE-NEW SERIES. 32:275-322.

Uzzan M., Bresteau C., Laharie D., Stefanescu C., Carbonnel F., Serrero M., Viennot S., Nachury M., Amiot A., Altwegg R. et al..  2021.  Tofacitinib as salvage therapy for patients hospitalized with refractory severe active ulcerative colitis: a GETAID multicenter prospective/retrospective cohort. JOURNAL OF CROHNS & COLITIS. 15:S305-S306.

Quirie A, Prati C, Wendling D, Totoson P, Demougeot C, Marie C.  2019.  Tofacitinib Enhanced Cerebral Brain-derived Neurotrophic Factor Levelsin a Rat Model of Rheumatoid Arthritis. ARTHRITIS & RHEUMATOLOGY. 71

Quirie A, Prati C, Wendling D, Totoson P, Demougeot C, Marie C.  2019.  Tofacitinib Enhanced Cerebral Brain-derived Neurotrophic Factor Levelsin a Rat Model of Rheumatoid Arthritis. ARTHRITIS & RHEUMATOLOGY. 71

Totoson P., Quirie A., Pedard M., Cefis M., Prigent–Tessier A., Prati C., Tournier M., Marie C., Demougeot C..  2021.  Tofacitinib exhibits vascular and cerebral benefits in rat adjuvant-induced arthritis. FUNDAMENTAL & CLINICAL PHARMACOLOGY. 35:16-17.

Totoson P, Peyronnel C, Quirie A, Pedard M, Cefis M, Bermont L, Prigent-Tessier A, Prati C, Tournier M, Wendling D et al..  2022.  Tofacitinib improved peripheral endothelial dysfunction and brain-derived neurotrophic factor levels in the rat adjuvant-induced arthritis model. FUNDAMENTAL & CLINICAL PHARMACOLOGY. 36:363-374.

Totoson P., Prati C., Wendling D., Quirie A., Marie C., Demougeot C..  2020.  TOFACITINIB REVERSED ENDOTHELIAL DYSFUNCTION IN RHEUMATOID ARTHRITIS: MECHANISTIC INSIGHTS FROM THE RAT ADJUVANT-INDUCED ARTHRITIS MODEL. ANNALS OF THE RHEUMATIC DISEASES. 79:250.

Dammak M, Boudia ORafik Mera, Messous MAyoub, Senouci SMohammed, Gransart C.  2019.  Token-Based Lightweight Authentication to Secure IoT Networks. 2019 16TH IEEE ANNUAL CONSUMER COMMUNICATIONS & NETWORKING CONFERENCE (CCNC).

Dammak M, Boudia ORafik Mera, Messous MAyoub, Senouci SMohammed, Gransart C.  2019.  Token-Based Lightweight Authentication to Secure IoT Networks. 2019 16TH IEEE ANNUAL CONSUMER COMMUNICATIONS & NETWORKING CONFERENCE (CCNC).

Boucheix J-M, Lowe R.  2020.  `Tokenized' Dynamic Diagrams: An Approach for Improving Mental Model Construction? DIAGRAMMATIC REPRESENTATION AND INFERENCE, DIAGRAMS 2020. 12169:481-484.

Bauge C, Leclercq S, Conrozier T, Boumediene K.  2015.  TOL19-001 reduces inflammation and MMP expression in monolayer cultures of tendon cells. BMC COMPLEMENTARY AND ALTERNATIVE MEDICINE. 15:217.

Roubaud G., Ozguroglu M., Penel N., Matsubara N., Mehra N., Kolinsky M.P, Procopio G., Feyerabend S., Joung J.Y, Gravis G. et al..  2020.  Tolerability of olaparib (OLA) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and homologous recombination repair (HRR) gene alterations: PROfound. ANNALS OF ONCOLOGY. 31:S515-S516.

Justet A, Klay D, Cottin V, Molina MMolina, Nunes H, Reynaud-Gaubert M, Naccache J-M, Manali E, Froidure A, Jouneau S et al..  2019.  Tolerance and efficacy of antifibrotic treatments in IPF patients carriying telomere related gene mutations. EUROPEAN RESPIRATORY JOURNAL. 54

Rossi-Semerano L, Fautrel B, Wendling D, Hachulla E, Galeotti C, Semerano L, Touitou I, Kone-Paut I, Grp MAIL1Study, CRI.  2015.  Tolerance and efficacy of off-label anti-interleukin-1 treatments in France: a nationwide survey. ORPHANET JOURNAL OF RARE DISEASES. 10:19.